Skip to main content

Penny Stock Momentum Watchlist (SING, CDIX, PXMD, ONCT)

One strategy used by experienced investors is to look for a specific pattern in the stock market, such as a rise in a company's stock price after a positive news release. It's almost like a vote of confidence in the company's future. 

Let's get into the stories of four stocks that have been capturing attention recently:

In a recent update on October 25, SinglePoint Inc. (OTCQB: SING), a sustainable lifestyle company focused on renewable energy and air purification, proudly shares the news of Frontline Power Solutions (FPS) achieving a substantial energy advisory agreement and a significant 7.1 million kWh energy services contract with a renowned national property management firm. 

This strategic move is poised to deliver approximately $110,000 in cost savings to the client during the contract's term. This accomplishment underscores FPS's role as a vital partner for clients seeking to enhance energy efficiency across their portfolios.

This achievement stands as a milestone, representing the second-largest energy contract in FPS's impressive track record. It highlights the potential for substantial growth, with FPS experiencing remarkable growth of over 100% since SinglePoint's strategic investment. 

Wil Ralston, CEO of SinglePoint, emphasizes the significance of these developments, stating, "Our dedicated sales teams across all divisions have exhibited unwavering commitment and expertise. Frontline Power Solutions embodies our integrated value proposition for our commercial customers. By combining our offerings in Solar, EV Charging, Energy Storage, and energy brokerage services with top-tier energy providers, we provide comprehensive energy solutions to our clients. This enables us to collaborate with our clients to reduce energy costs, build long-term value, and align with green energy mandates. These long-term contracts not only represent a recurring revenue stream for SinglePoint but also demonstrate our commitment to sustainability and a leading position in the market."

Frontline Power Solutions operates as a licensed energy services company (ESCO) in fifteen states, delivering electric and gas contracts to commercial entities operating in deregulated markets. Leveraging two decades of experience in the energy industry, FPS provides clients with sophisticated energy procurement and management strategies, ensuring optimal outcomes in today's complex energy landscape.

The deregulated energy market in the United States offers significant opportunities for companies like Frontline Power Solutions, allowing businesses and consumers to select their energy providers in a competitive marketplace. With numerous states embracing energy deregulation, this sector has witnessed substantial growth, providing a vast platform for innovative energy solutions and sustainable practices. This market encourages competition and promotes the adoption of renewable energy sources, aligning with both national and global sustainability goals.

In summary, this recent achievement underscores Frontline Power Solutions' pivotal role in the energy sector, SinglePoint's (OTC: SING) commitment to sustainability and growth, and the immense potential within the U.S. deregulated energy market.

Cardiff Lexington Corporation (OTC: CDIX), a forward-thinking player in the U.S. healthcare industry, is strategically expanding its healthcare network, which includes hospitals, clinics, and specialized healthcare services. Recently, CDIX released its financial results for the second quarter ending June 30, 2023, and the numbers reveal substantial growth. 

One key highlight from the financial report is the remarkable increase in total assets, showing a 20% rise. The company's total assets jumped from $13,353,357 as of December 31, 2022, to $16,053,519 by June 30, 2023. 

Revenue also saw a substantial boost. For the three months ending June 30, 2023, revenue increased by 12.6% compared to the same period in 2022, with a net increase of $391,578. Over the six months ending June 30, 2023, the company reported a 5.9% increase in revenue, amounting to $355,226. 

Gross profit showed an impressive net increase of 19.3% for the three months ending June 30, 2023, totaling $385,210. For the six months ending June 30, 2023, the gross profit increased by 12.7%, or $481,963. 

Perhaps one of the most noteworthy aspects of the financial report is the significant surge in net income. The company reported a 1,220.0% net increase in net income for the three months ending June 30, 2023, resulting in $877,904. For the six months ending June 30, 2023, the net income experienced an astonishing 149.3% increase, amounting to $2,424,367. 

On September 29, 2023, Cardiff Lexington Corporation took a significant step forward by entering into a Revolving Purchase and Security Agreement. This agreement will provide financing for the company's wholly-owned subsidiary, Nova Ortho and Spine, LLC, to support operational growth. With the ability to sell approved pools of accounts receivable up to an advance amount of $4,500,000, this financial instrument offers the working capital required for continued expansion.

PaxMedica Inc. (NASDAQ: PXMD) is making waves in the clinical-stage biopharmaceutical arena with its pioneering approach to anti-purinergic drug therapies (APT). These therapies are intended to treat difficult neurologic disorders such as Autism Spectrum Disorder (ASD) and the debilitating Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS), which cause patients to face both physical and cognitive challenges.

At the heart of PaxMedica's mission lies PAX-101, an intravenous suramin formulation that takes center stage in the company's efforts to address Autism Spectrum Disorder. This flagship program is a beacon of hope for ASD patients, promising advancements and evaluations in the pursuit of effective treatment. Beyond ASD, PaxMedica is also exploring the potential applications of PAX-101 for conditions like ME/CFS.

Recently, PXMD reached a significant milestone by successfully completing a type-B meeting with the U.S. Food and Drug Administration (FDA). The meeting with the FDA focused on the positive results of the PAX-HAT-301 study, specifically Suramin's role in combating Stage One Human African Sleeping Sickness caused by Trypanosoma brucei rhodesiense. This parasitic disease is rare and can be fatal if left untreated.

During this meeting with the FDA, PaxMedica received constructive feedback that is expected to play a vital role in the path to filing a New Drug Application (NDA). The NDA filing is projected to take place in the second half of 2024, marking a critical step forward for PaxMedica. The bulk of the work required to achieve this milestone centers on the completion of commercial lots of PAX-101, all in accordance with CMC regulatory guidelines. This production process is already in progress and is anticipated to conclude in the first half of 2024.

Howard Weisman, CEO and Chairman of PaxMedica, expressed the significance of this development, stating, "This is an important turning point for our young company, and we are very pleased with the guidance that the FDA has provided us in this meeting. We look forward to urgently completing the necessary steps in the coming months to clear the path to submit our first NDA for PAX-101."

PXMD is making remarkable strides in the field of anti-purinergic drug therapies. With its flagship program, PAX-101, and recent positive interactions with the FDA, the company is on a trajectory to make a meaningful impact on the treatment of challenging neurologic disorders, providing hope and innovative solutions to those in need.

Oncternal Therapeutics (NASDAQ: ONCT) is a clinical-stage biopharmaceutical company specializing in the development of innovative oncology therapies. They are committed to addressing critical unmet medical needs in the field of cancer treatment, particularly focusing on hematological malignancies and prostate cancer. One of their promising treatments is ONCT-534, a dual-action androgen receptor inhibitor (DAARI) showing potential in treating metastatic castration-resistant prostate cancer (mCRPC).

Recently, the company issued a press release detailing the significant development of the U.S. Food and Drug Administration (FDA) granting ONCT-534 a Fast Track designation. For penny stock investors, this designation is a significant development to keep a close eye on. It indicates that ONCT-534 holds promise for patients with mCRPC who haven't responded to existing treatments. The FDA's Fast Track designation is akin to a green light that could accelerate the availability of this treatment option.

ONCT-534 works by targeting the androgen receptor (AR) in cancer cells, inhibiting their growth, and potentially offering treatment options for patients with various AR-related issues. This innovative mechanism has the potential to be a game-changer in prostate cancer treatment.

For investors in penny stocks, the FDA's Fast Track designation is an essential development. It suggests that ONCT-534 might have the potential to revolutionize prostate cancer treatment. It's a development worth watching, as it could have significant implications for both patients and investors.

ONCT is advancing toward a potential breakthrough in prostate cancer treatment with the FDA's Fast Track designation, making it a noteworthy development for penny stock investors to monitor closely, as detailed in the company's recent press release.



Disclaimers: CapitalGainsReport (CGR) is not operated by a licensed broker, a dealer, or a registered investment adviser. This content is for informational purposes only and is not intended to be investment advice. The Private Securities Litigation Reform Act of 1995 provides investors a safe harbor in regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions, or future events or performance are not statements of historical fact may be forward looking statements. Forward looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through use of words such as projects, foresee, expects, will, anticipates, estimates, believes, understands, or that by statements indicating certain actions & quote; may, could, or might occur. Understand there is no guarantee past performance will be indicative of future results. Investing in micro-cap and growth securities is highly speculative and carries an extremely high degree of risk. It is possible that an investors investment may be lost or impaired due to the speculative nature of the companies profiled. CapitalGainsReport (CGR) is owned by RazorPitch Inc. and has been retained by SinglePoint to assist in the production and distribution of content related to SING. 'CGR'  is responsible for the production and distribution of this content. It should be expressly understood that under no circumstances does any information published herein represent a recommendation to buy or sell a security. This content is for informational purposes only, you should not construe any such information or other material as legal, tax, investment, financial, or other advice. Nothing contained in this article constitutes a solicitation, recommendation, endorsement, or offer by CapitalGainsReport/RazorPitch or any third party service provider to buy or sell any securities or other financial instruments. All content in this article is information of a general nature and does not address the circumstances of any particular individual or entity. Nothing in this article constitutes professional and/or financial advice, nor does any information in the article constitute a comprehensive or complete statement of the matters discussed or the law relating thereto. CGR/RazorPitch is not a fiduciary by virtue of any persons use of or access to this content.

Media Contact
Company Name: Capital Gains Report
Contact Person: Mark McKelvie
Email: Send Email
Country: United States

Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.